

# Acasti Pharma Inc

09:26 14 Feb 2020

## Acasti Pharma making 'steady progress' on CaPre trials, says CEO

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CEO Jan D'Alvise said that the company was making "steady progress" with the audit of its TRILOGY 1 study data of its lead drug, CaPre.

The Laval, Quebec-based company reported preliminary topline results earlier this week for the primary endpoint from its Phase 3 TRILOGY 1 trial for CaPre, an omega-3 phospholipid to treat severe hypertriglyceridemia.

Acasti reported a 30.5% median reduction in triglyceride (TG) levels among all patients receiving CaPre, compared to a 27.5% median reduction in triglyceride levels among patients receiving placebo at 12 weeks.

### READ: Acasti Pharma updates on TRILOGY 1 and TRILOGY 2 Phase 3 trials of lead heart drug CaPre

Despite monitoring activities conducted throughout the TRILOGY 1 trial to ensure adherence to the protocol and identify protocol violations, Acasti said it subsequently identified some unexpected and inconsistent findings that it believes may have negatively contributed to the overall topline results.

These findings are now being further explored via a comprehensive and rigorous review of data and patient medical records by an independent team of auditors, the firm said in a statement.

"This data has been very informative, and provided we have the FDA's support, any learnings we can take from this investigation that may allow us to adjust the Statistical Analysis Plan (SAP) for TRILOGY 2, gives us a better chance of accurately reflecting the clinical value that we see in CaPre," D'Alvise told shareholders on Friday.

"As previously noted, we have confirmed that there is established precedent for the FDA accepting post-hoc analyses of study results, assuming the analyses are transparent, well justified and well supported. We are moving as quickly as possible now to complete this work and secure a meeting with the FDA."

### DEEP DIVE: Acasti Pharma edging closer to commercializing CaPre as it eyes topline clinical data for Christmas

Acasti said it plans to keep TRILOGY 2 blinded until it meets with the FDA. The firm anticipates the unblinding of the topline results for TRILOGY 2 sometime in calendar Q3 of 2020, to allow time for the FDA meeting, it told shareholders.

Accordingly, key secondary and exploratory endpoints from both TRILOGY 1 and TRILOGY 2 studies, would now be expected after the unblinding of TRILOGY 2 results, D'Alvise said. "We are moving as quickly as possible and will provide material updates when available."

The firm also reported its fiscal 3Q 2020 results showed a cash balance of C\$25.7 million, which is expected to fund ongoing study investigations.

**Price:** 1.01

**Market Cap:** \$93.41 m

#### 1 Year Share Price Graph



August 2019 February 2020 July 2020

#### Share Information

**Code:** ACST

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.05	0.35

**Sector:** Pharma & Biotech

**Website:** [www.acastipharma.com](http://www.acastipharma.com)

#### Company Synopsis:

Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.

action@proactiveinvestors.com

Net loss for the period was C\$15.7 million or C\$0.18 per share, compared to a net loss of C\$4.6 million or C\$0.07 per share for the quarter ended December 31, 2018. According to Acasti, the higher net loss was primarily due to the non-cash financial loss of C\$7.9 million for the three months ended December 31, 2019, due mostly to the change in the fair value of the warrant derivative liability, partially offset by a decrease in the number of warrants.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).